T he spine is the most common location for osseous metastases with up to 40% of cancer patients affected.
With longer survival times, other issues affecting quality of life and pain have emerged. The risk of VCFs in vertebrae treated with SBRT has only recently been investigated. A prospective trial by Rose et al. 33 revealed that 39% of treated sites had new or progressing fractures, with larger, lytic metastases located in the lower spine at highest risk after SBRT. Authors of biomechanical and imaging studies have attempted to create similar risk models to predict VCF in spinal metastases. 7, 8, 38, 42, 43 These studies have focused on the main factors of anatomical location of the lesion (cervical, thoracic, lumbar), size and geometry of the lesion, and nature of the lesion (lytic, blastic, mixed), which have all been shown to be significant predictors of VCF. More recent expert consensus from the Spine Oncology Study Group has led to the identification of spinal instability factors. 10, 11, 45 The primary goal of predicting VCF after SBRT is to intervene at an earlier point in time to prevent pain and worsening of functional status. Minimally invasive techniques, such as kyphoplasty and vertebroplasty, have proven effective in relieving pain and stabilizing metastatic spine lesions. [2] [3] [4] 12, 14, 16, 20, 22, 29 Stereotactic body radiotherapy itself sometimes requires lengthy setup times and intervention before treatment to both stabilize at-risk fractures and allow patients to be comfortably immobilized. In addition, post-SBRT prophylactic interventions for those deemed at risk for VCF can reduce the time spent in bed rest, sequelae such as deep venous thrombosis, and possibly mortality. 24 We retrospectively evaluated data to review the risk of VCF and associated factors in patients treated with SBRT for spinal metastases at our institution. The primary purpose of this study was to determine the incidence of VCF in patients treated with SBRT for spinal metastases. Our secondary objective was to identify risk factors for the development of VCF posttreatment.
Methods

Patient Selection
Patients enrolled in 2 prospective protocols for spinal metastatic disease (209 patients) and treated with SBRT between November 2002 and November 2009 at the M.D. Anderson Cancer Center were reviewed for inclusion in this study. All patients received SBRT based on recommendations from multidisciplinary evaluation by neurosurgeons, radiation oncologists, and radiation physicists. Patients had confirmed solid organ metastases to the spine based on primary tumor diagnosis and MR imaging. Patients with preexisting fractures were included in the study. Exclusion criteria consisted of unstable spinal architecture, prior surgery, paraspinal tumors not involving a VB, or neurological compromise from cord compression. The neurosurgery team evaluated all patients for unstable spinal lesions prior to treatment. Patients whose spines were mechanically unstable were ineligible for the study until their spines were surgically stabilized. Multiple treatment levels with or without prior radiation up to but not exceeding 45 Gy were allowed.
Treatment and Evaluation
Stereotactic body radiotherapy was delivered as previously described. 40 Treatment plans consisted of 1, 3, or 5 fractions for median doses of 18, 27, and 30 Gy, respectively. Doses were constrained so that the maximum dose to the spinal cord was 9-10 Gy.
Full spinal MR imaging studies were obtained pretreatment and 3, 6, 9, and 12 months after treatment and then every 6 months thereafter. Magnetic resonance images were evaluated for tumor involvement, radiographic tumor progression, and VCF. The percentage of tumor involvement was estimated using digital measurements and was classified on a quintile ordinal scale. Lytic, sclerotic, or mixed tumors were classified based on CT appearance. Vertebral compression fracture was measured by comparing the VB height on prior MR imaging or, if unavailable, an average height of the vertebrae immediately superior and inferior and then classifying on a quintile ordinal scale. Fracture outcome was defined as a new or progressing fracture. End plate-only fractures were included in the study, as were all other fractures. A progressing fracture was defined as an increase in fracture from normal vertebrae to end plate fracture (that is, new fractures), end plate-only fractures and up to a 20% loss of height, or an increase in the loss of height sufficient to move into the next quintile percentage of compression as per a prior report. 33 Pain scores were self-reported average back pain levels based on the 11-point (0-10) Brief Pain Inventory at baseline, the 4-week follow-up, and the time of fracture. 6 Obesity was defined as a body mass index ≥ 30. Age was recorded at the first SBRT session. Bisphosphonate use was recorded if the drug was used within 6 months of SBRT treatment. The KPS score and the use of narcotics were recorded pretreatment, posttreatment, and at the time of fracture (that is, the time the fracture was seen on imaging).
Statistical Analysis
Logistic regression and Cox proportional hazard models were used to determine significant factors associated with fracture progression. Fracture and disease progression time data were obtained from Kaplan-Meier plots with significance determined by log-rank analysis. Pain correlation data were analyzed using the Student t-test and linear regression models. For all analyses, statistical significance was determined by a p value < 0.05.
Results
Ninety-three patients, consisting of 44 men and 49 women, were eligible for inclusion in the study. The overall mean age at SBRT was 56 years (range 21-88 years). The median clinical and imaging follow-up was 16 and 14.9 months, respectively. At the time of analysis, 43 patients were still alive and 50 had died. Nineteen patients were obese. Thirty-three patients had noted the use of bisphosphonates within 6 months of SBRT. The median radiation dose delivered was 27 Gy (Table 1) . One hundred twentythree VBs were treated (Table 2 and Fig. 1 ).
Thirty-four preexisting fractures (28%) were identified in 27 patients (29%), with 17 of those fractures involving the end plate only. Progressing fractures were identified in 25 VBs (20%), 14 (11%) of which were new. The median (27) 18 (27) 45 (27) 5 fractions 15 (30) 1 (20) 16 (30) * CRT = conventional radiotherapy; FU = follow-up. time to fracture progression was 3 months after SBRT. The median time from SBRT to fracture was 14 months as measured by the Kaplan-Meier method. The mean loss of VB height at the time of SBRT, at the first noted fracture progression, and at the final MR imaging follow-up was 0%-20%, 20%-40%, and 20%-40%, respectively. Logistic regression and Cox proportional hazards model data are detailed for univariate data and multivariate data in Table 3 . Bisphosphonate use, > 40% of VB involvement, lesion location above the T-10 level, and KPS score were not significant. The effects of tumor involvement on VB compression risk are shown in Table 4 .
Kaplan-Meier plots for an age > 55 years (HR 4.98, 95% CI 2.25-11.00, p < 0.01), tumor progression (HR 3.22, 95% CI 1.22-8.50, p < 0.02), lytic versus sclerotic appearance (HR 2.25, 95% CI 1.02-4.96, p < 0.05), and preexisting fracture (HR 9.53, 95% CI 3.32-27.33, p < 0.01) were significant, as seen in Fig. 2 .
Initial pain scores had a median value of 2 and a mean of 2.3 ± 2.2, with a post-SBRT median of 1 and mean of 1.5 ± 1.8. The median change in the pain score following SBRT was 0, and the mean change was -0.8 ± 1.7. At the time the fracture was noted, the median pain score was 3 and the mean was 2.6 ± 2.1. The median change in the pain score from post-SBRT to fracture progression was 0, and the mean change was 0.3 ± 2.0.
The initial median KPS score was 90 and the mean was 84 ± 10, with a post-SBRT median score of 90 and mean of 85 ± 11. The median change in the KPS score was 0 and the mean was 1 ± 10. At the time the fracture was noted, the median KPS score was 80 and the mean was 78 ± 10. The median change in the KPS score from post-SBRT to fracture progression was 0 and the mean was -6 ± 8. An existing fracture was associated with higher initial pain scores (p < 0.03, t-test); however, it was not associated with pain scores after SBRT. The size of the preexisting VCF and tumor burden were not significantly correlated with higher pain scores. At the time of noted fracture progression there was a trend toward higher average pain scores but no significant change in the median value. Prior to SBRT 47% of the patients were using narcotics; after SBRT 44% of the patients were using them. Seventy-three percent of the patients with progressing fractures were using narcotics.
Fifteen vertebral bodies were treated with kyphoplasty or vertebroplasty after SBRT, with 5 of these procedures being performed for preexisting VCFs that did not progress. Tumor progression was noted at 32 treated vertebral bodies (26%), with 5 months' median time to tumor progression.
Discussion
In this study we revealed a significant 20% risk of VCF and we identified risk factors associated with VCF after SBRT. In comparison with a prospective study by Rose et al., 33 we found a lower overall risk of VCF (20% vs 39%). The patient cohorts in the 2 studies were similar in many regards including age, sex, frequency of lytic or sclerotic appearance on CT, lesion location, prevalence of preexisting fractures, and total follow-up. The present study showed that larger, lytic lesions corresponded with fracture progression, which was consistent with prior findings.
38,43 A lumbar location was associated with an increased risk but was nonsignificant in our cohort. In contrast to large studies looking at osteoporotic patients, neither study showed a bisphosphonate effect. 1 There are several notable differences between the current study and the Rose et al. 33 study, including histology frequency, tumor burden, and time to fracture. Our study population had a greater proportion of patients with breast metastases (16% vs 6%) but a lower proportion of patients with melanoma (0% vs 13%) and prostate (< 1% vs 13%) metastases. In our breast metastases cohort, no fractures were noted. With regard to tumor burden, our population had larger metastases treated, with 33% having > 80% VB involvement as compared with 14% in the Rose et al. study. Preexisting fractures had a significantly greater effect in our cohort and led to earlier fracture progression, with a median progression-free survival time from a fracture event of 14 months as compared with 25 months for patients without preexisting fractures. Lastly, we included patients who had received conventional radiotherapy to the spine prior to SBRT. However, no sig- nificant differences were noted in the study population or fracture risk.
Factors unique to the current study include the significant effects of an older age, a preexisting fracture, and increased baseline pain scores. Obesity was a protective factor. Increased age and preexisting VCF as factors predicting further fracture are consistent with results of other studies investigating VCF in postmenopausal women, another high-risk group. 24, 27 Similar to findings in other reports, obesity was protective in terms of the risk for VCF for reasons possibly related to increased bone density. 34 It is difficult to compare the prevalence of fractures with that in other studies given the variation in patient characteristics, tumor control rates, and radiation dose equivalents between studies. In a cross-sectional analysis of spinal metastases without treatment, one study demonstrated that 7.4% of infiltrated vertebrae had a fracture as defined by ≥ 10% loss of height. 38 One study reported that after conventional spinal radiotherapy, 31% of patients had vertebral collapse; however, these patients had more advanced, symptomatic spinal cord compression. 28 The only current data available after radiosurgery is from the study by Rose et al. 33 The higher doses used in SBRT can potentially cause weakened bone structure. Increased rates of rib fractures have been reported in patients receiving higher doses of whole-breast radiation. 31 Future studies such as RTOG 06-31, a phase II/III study of SRBT for localized spine metastasis, will help to further define the risk of VCF after SBRT.
Properly selecting patients for prophylactic kyphoplasty or vertebroplasty and determining the optimum sequence of these procedures and spine SBRT remain difficult tasks. At the time of evaluation, elevated pain scores were associated with preexisting fracture but did not correlate with the size of the fracture or the tumor burden. Postradiotherapy pain levels decreased, probably from treatment effect, and had no significant correlation with preexisting fracture, making the separation of tumor pain from fracture pain difficult at the first evaluation. Overall pain and narcotic use trended upward at the time of fracture progression; however, this difference did not reach statistical significance. Possible explanations for this lack of significance include the presence of subacute fracture, a follow-up occurring outside the 4-to 6-week acute pain window, and lack of sufficiently significant loss of VB height at the time of measurement. 9, 25, 41 In general, due to a limited subset of patients experiencing VCF events, an analysis of back pain was difficult. Pain is a major symptom seen to correlate with the KPS score as well. In a prospective trial looking at VCF in osteoporotic women, disability and pain were reported with long-term follow-up. 30 Combining tumor control with spine stabilization in patients with preexisting fracture, Gerszten et al. 16 used kyphoplasty with implanted fiducials to guide singledose SBRT using the CyberKnife system. While neither the amount of fracture compression nor individual pain changes was noted, they found the methods to be safe and effective, with 24 of 26 patients experiencing pain relief. Whether this combined modality is necessary for durable pain relief and/or spine stabilization remains to be seen. Stereotactic body radiotherapy itself has demonstrated pain relief, with many fractures lacking symptoms. In addition, the population at highest risk for fracture is the elderly with larger metastases, a population with probable lower life expectancy and potentially higher risks of procedure-related complications. Clinical judgment is currently used to select appropriate patients and will be aided by additional data becoming available.
Based on these data, intervention can possibly be delayed for patients with asymptomatic, stable spinal elements without preexisting fracture. Closer follow-up may be warranted for those with larger, lytic lesions and for patients with an older age and a poor performance status. For those with continued or acute pain and a decreased performance status, early intervention might relieve pain as reported in the Vertos II (vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures) trial for acute osteoporotic fracures. 25 A significant point is that many patients enrolled in Vertos II had spontaneous relief from pain prior to intervention. Further investigation into whether a watch-and-wait approach vis-à-vis immediate intervention for SBRT-treated spine metastases is needed.
This study is limited by several factors including the absence of a control arm, its retrospective analysis of a prospective protocol, and the absence of VCF-specific imaging other than spinal MR imaging. We did not analyze the effects of tumor structure with regard to cross-sectional area or posterior element analysis. In addition, while kyphosis or scoliosis was qualitatively analyzed, no baseline spinal angulation was recorded since these changes were typically the result of the VCF occurring after treatment and because few patients had it as a preexisting condition. Bone densitometry data would have been useful to normalize data; however, the goal of the original protocol did not include collection of this parameter.
Conclusions
Stereotactic body radiotherapy is associated with a significant risk (20%) of VCF. Risk factors for VCF include an age > 55 years, a preexisting fracture, and existing pain. These risk factors may aid in the selection of which spinal SBRT patients should be considered for prophylactic vertebral stabilization or augmentation procedures.
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